Asset Details
Do you wish to reserve the book?
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome
Do you wish to request the book?
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome
2025
Overview
Shwachman-Diamond syndrome (SDS) is characterized by neutropenia, exocrine pancreatic insufficiency, and bony abnormalities with an increased risk of myeloid neoplasia. Almost all cases of SDS result from biallelic mutations in Shwachman-Bodian-Diamond syndrome (SBDS). SBDS interacts with elongation factor–like 1 (EFL1) to displace eukaryotic initiation factor 6 (EIF6) from the 60S ribosomal subunit. Released EIF6 permits the assembly of ribosomal large and small subunits in the cytoplasm. Decreased EIF6 levels due to haploinsufficiency or missense mutations, which lead to decreased protein expression, may provide a somatic genetic rescue and antileukemic effects. We observed accumulation of EIF6 protein in sbds -KO zebrafish models, confirmed this accumulation in patient-derived tissues, and correlated these with changes in ribosomal proteins and tumor protein p53 (TP53) pathways. The mechanism of action for this adaptive response is unknown. To address this, we generated eif6 -KO zebrafish, which do not survive more than 10 days after fertilization. We also created 2 mutants with low Eif6 expression, i.e., 5%–25% of WT levels, that could survive until adulthood. We bred them with sbds -null strains and analyzed their phenotype and biochemical properties. Low Eif6 levels reduced Tp53 pathway activation but did not rescue neutropenia in Sbds-deficient zebrafish. Further studies elucidating the interplay between SBDS, EIF6, and TP53 and cellular stress responses offer promising insights into SDS pathogenesis, somatic genetic rescue, and therapeutic strategies.
Publisher
American Society for Clinical Investigation
Subject
/ Anemia, Macrocytic - genetics
/ Anemia, Macrocytic - metabolism
/ Anemia, Macrocytic - pathology
/ Animals
/ Bone Marrow Diseases - genetics
/ Bone Marrow Diseases - metabolism
/ Bone Marrow Diseases - pathology
/ Cellular signal transduction
/ Diseases
/ Eukaryotic Initiation Factors
/ Exocrine Pancreatic Insufficiency - genetics
/ Exocrine Pancreatic Insufficiency - metabolism
/ Exocrine Pancreatic Insufficiency - pathology
/ Genes
/ Genetics
/ Humans
/ Mutation
/ Oncology
/ Patients
/ Peptide Initiation Factors - genetics
/ Peptide Initiation Factors - metabolism
/ Proteins
/ Ribosomal Proteins - genetics
/ Ribosomal Proteins - metabolism
/ RNA
/ Siblings
/ Tumor Suppressor Protein p53 - genetics
/ Tumor Suppressor Protein p53 - metabolism
